⌕
Sana Biotechnology · SANA · Nasdaq
Tenet 34 · Weak
Compare
$1.88−6.93%At closeTenet 34 · Weak
$1.88−0.14 (−6.93%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Sana Biotechnology (SANA) Stock

Sana Biotechnology (SANA) closed at $1.88 on Nov 16, 2026; its Tenet Score is 34 of 100 against 440 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$1.88
Nov 16, 2026
Market cap
$563.3M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
1.86 – 5.49
low → high
Tenet Score
34/100
Weak · 440 Healthcare peers

Industry: Drugs · see every company filed here →

Sana Biotechnology Inc scores 34/100. Weak. Quality is the soft spot versus 440 Healthcare peers. Insufficient inputs: Tenet 34 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=440
34/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
59
Quality
10
Health
33
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityFHealthDGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
3.1×
cap ÷ Sep 30, 2026 book value, Nov 16, 2026 close
P/S
—
no P/S on file
ROE
−79%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
1.77
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 4y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes…

Composite computed Nov 17, 2026 · peer basis: Healthcare (n=440) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 49 US ETFs · top wrappers by weightSee all ETFs holding SANA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Sana Biotechnology in?

Sana Biotechnology is in the Healthcare sector and the Drugs industry.

What is Sana Biotechnology's Tenet Score?

Sana Biotechnology's Tenet Score is 34 out of 100, ranked against 440 Healthcare peers as of Nov 17, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.